Korea South
3billion, founded in 2016, is revolutionizing the realm of genetic testing for rare diseases by leveraging AI-powered genomics. Headquartered in South Korea, this company is on a mission to make rare disease diagnosis faster, more accurate, and accessible on a global scale.
With over 80,000 patients tested in collaboration with 800+ medical institutions across 80+ countries, 3billion has quickly established itself as a leader in its field. A key differentiator is their unique daily reanalysis system, which provides continual updates to diagnoses at no additional cost to patients, ensuring a comprehensive and evolving approach to treatment.
The company's technology and global impact earned them a listing on KOSDAQ in 2024, underlining robust growth and innovation in the healthcare and pharmaceutical industries. 3billion stands at the intersection of healthcare and technology, poised for significant expansion and offering compelling potential for investors. Despite no recent investment rounds, the firm remains a promising candidate for future capital infusion in the health-tech sector.
